- Home
- IONS vs ZWS Comparison
IONS vs ZWS Comparison
Compare IONS & ZWS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- ZWS
- Stock Information
- Founded
- IONS 1989
- ZWS 1891
- Country
- IONS United States
- ZWS United States
- Employees
- IONS N/A
- ZWS N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- ZWS Industrial Machinery/Components
- Sector
- IONS Health Care
- ZWS Industrials
- Exchange
- IONS Nasdaq
- ZWS Nasdaq
- Market Cap
- IONS 5.9B
- ZWS 5.9B
- IPO Year
- IONS 1991
- ZWS 2012
- Fundamental
- Price
- IONS $37.41
- ZWS $35.35
- Analyst Decision
- IONS Buy
- ZWS Buy
- Analyst Count
- IONS 18
- ZWS 6
- Target Price
- IONS $57.59
- ZWS $37.67
- AVG Volume (30 Days)
- IONS 1.5M
- ZWS 568.3K
- Earning Date
- IONS 07-31-2025
- ZWS 07-29-2025
- Dividend Yield
- IONS N/A
- ZWS 1.02%
- EPS Growth
- IONS N/A
- ZWS 40.41
- EPS
- IONS N/A
- ZWS 0.98
- Revenue
- IONS $717,253,000.00
- ZWS $1,581,500,000.00
- Revenue This Year
- IONS $7.98
- ZWS $4.31
- Revenue Next Year
- IONS $16.09
- ZWS $4.71
- P/E Ratio
- IONS N/A
- ZWS $35.92
- Revenue Growth
- IONS N/A
- ZWS 3.22
- 52 Week Low
- IONS $23.95
- ZWS $27.74
- 52 Week High
- IONS $52.34
- ZWS $41.15
- Technical
- Relative Strength Index (RSI)
- IONS 68.61
- ZWS 49.12
- Support Level
- IONS $34.78
- ZWS $35.09
- Resistance Level
- IONS $37.54
- ZWS $36.24
- Average True Range (ATR)
- IONS 1.06
- ZWS 0.59
- MACD
- IONS 0.07
- ZWS -0.20
- Stochastic Oscillator
- IONS 95.44
- ZWS 29.50
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About ZWS Zurn Elkay Water Solutions Corporation
Zurn Elkay Water Solutions Corp designs procures, manufactures, and markets a range of clean water solutions for drinking water, hygiene, and sustainable water management. The company's product portfolio includes professional-grade water control and safety, water distribution and drainage, drinking water, finish plumbing, hygienic, environmental and site works products for public and private spaces.